Clinical research (research involving human subjects) may include the evaluation of therapies, treatments, devices, medications, surgeries, and/or diagnostic tools. The results from clinical research advance the efficacy and safety of new treatments and directly improve patient care and quality of life.

The Division of Infectious Diseases has a research team whom coordinates all clinical research with the Infectious Diseases clinical faculty. In addition to clinical research, the faculty members conduct laboratory research both at the UC Davis Medical Center and on the UC Davis Campus

Each type of clinical research plays an integral part in strengthening our knowledge of certain diseases or conditions. With clinical research, we can implement better techniques to diagnose, treat, and prevent human diseases and conditions.

 

Clinical Trials

The majority of clinical research consists of clinical trials, which may be sponsored or funded by physicians, foundations, federal health agencies (such as the National Institutes of Health), pharmaceutical companies, or university grants. A clinical trial is a study that looks for new ways to prevent, detect, diagnose, and/or treat a disease or condition. Clinical trials are research projects that have two main objectives in mind: patient safety and disease treatment/prevention. Patients are at the forefront of medicine when they choose to be a participant in a clinical trial. Not only are they contributing to the medical and scientific understanding of their disease, but they also have access to the newest treatments.

 

There are different phases of clinical trials. Although each phase has a different purpose, each phase also focuses on evaluating the safety of the treatment being tested. 

  • Phase I trials test the treatment for the first time to make sure it is safe and evaluate any side effects
  • Phase II trials test a treatment to see how effective it is
  • Phase III trials test a treatment to compare it to standard treatments
  • Phase IV trials are when the treatment is already approved by the FDA, but researchers are still following the treatment to ensure safety and  to measure its benefits 

After a Phase I or Phase II trial, the researchers decide whether they want to move to the next phase or to stop testing the treatment. When a Phase III trial is completed, researchers analyze the data and determine their medical significance. Results from clinical trials are often published in scientific journals.

Clinical research studies are very different from regular medical care. Your primary care physician will diagnose and treat you for an illness or condition. Clinical researchers gather new information to help improve future medical care.

For additional information, contact the research team or click on the FAQ tab on this page.

 

Clostridium difficile Infection 

Study Title: A randomized, double-blinded, active-controlled study of CB-183,315 in patients with Clostridium difficile associated diarrhea 

Study Type: Phase III 

  • Purpose: The goal of this trial is to demonstrate the noninferiority of CB-183,315 versus oral vancomycin in adult subjects with CDAD, as well as evaluate the safety of CB-183,315 in subjects with CDAD.
  • Principal Investigator: Stuart Cohen, M.D.
  • Study Contacts: Heather Wood—p. 916-734-0130; email: hrwood@ucdavis.edu
    Muzna Naqvi—p. 916-734-8033; email: manaqvi@ucdavis.edu
     

Study Title: A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD) 

Study Type: Phase III 

  • Purpose: The goal of this trial is to determine if 10 days of orally administered cadazolid is non-inferior to orally administered vancomycin in subjects with CDAD.
  • Principal Investigator: Stuart Cohen, M.D.
  • Study Contact: Joanna Tripet-Diel—p. 916-734-8101; email: jrtdiel@ucdavis.edu
    Heather Wood—p.  916-734-0130; email: hrwood@ucdavis.edu

 

Influenza

Study Title: A double blind, randomized, stratified, multi-center trial evaluating conventional and double dose oseltamivir in the treatment of immunocompromised patients with influenza 

Study Type: Phase III 

  • Purpose: The goal of this trial is to evaluate the safety and tolerability of oseltamivir for the treatment of influenza in immunocompromised patients and characterize the effects of oseltamivir in immunocompromised patients on the development of resistant influenza virus.
  • Principal Investigator: Hien Nguyen, M.D.
  • Study Contact: Muzna Naqvi—ph: 916-734-8033 email: manaqvi@ucdavis.edu
    Joanna Tripet-Diel—ph: 916-734-8101; email: jrtdiel@ucdavis.edu


Phaeohyphomycosis

Study Title: A case registry of patients with phaeohyphomycosis 

Study Type: Case Registry 

  • Purpose: The goal of this study is to evaluate the all-cause mortality and clinical response at 6 weeks post-diagnosis of phaeohyphomycosis, stratified by type of infection. This study will also evaluate antifungal susceptibility and antifungal drug safety.
  • Principal Investigator: George Thompson, M.D.
  • Study Contact: Heather Wood—ph: 916-734-0130; email: hrwood@ucdavis.edu
    Muzna Naqvi —ph:  916-734-8033 email: manaqvi@ucdavis.edu
     

Invasive Candidiasis/Candidemia

Study Title: A prospective, multicenter, open-label, randomized, comparative study to estimate the safety, tolerability, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis (including candidemia) in hospitalized nonneutropenic adults

Study Type: Phase II

  • Purpose: The goal of this study is to evaluate the safety and tolerability of two doses of SCY-078 in the therapy of invasive candidiasis.
  • Principal Investigator: George Thompson, M.D.
    Study Contact: Muzna Naqvi —ph:  916-734-8033 email: manaqvi@ucdavis.

 

AFFILIATED PROGRAMS

Center for Comparative Medicine
Clinical and Translational Science Center
California National Primate Research Center
Department of Medical Microbiology and Immunology
Institute for Regenerative Cures
Center for Biophotonics
Center for Vectorborne Diseases